All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Japanese approval of axicabtagene ciloleucel for the treatment of R/R large B-cell lymphomas
On January 22, 2021, it was announced that the Japanese Ministry of Health, Labour and Welfare approved the use of axicabtagene ciloleucel, a CD19 chimeric antigen receptor T-cell therapy, for the treatment of relapsed/refractory (R/R) large B-cell lymphomas, including primary mediastinal B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma. This approval was based on the results from the pivotal ZUMA-1 study, previously reported on the Lymphoma Hub, and data from a phase II trial, specifically looking at efficacy and safety in Japanese patients (n = 16).1
The Japanese trial showed an objective response rate of 86.7% (95% CI, 59.5–98.3) and a similar overall safety and tolerability profile as that reported for ZUMA-1. Axicabtagene ciloleucel is also approved by the U.S Food and Drug Administration (FDA) and European Medicines Agency (EMA) for patients with R/R B-cell lymphomas.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content